initi buy quick action less steroid new
auph recent report posit ph iii data show lead asset voclosporin vc
effect safe lupu nephriti ln -- remov safeti overhang
critic given clear need approv ln agent vc differenti profil
believ auph appeal oppti ahead ln ph iii also believ vc
potenti fsg dri eye syndrom de de-risk
jefferi lead left bookrunn auph decemb secondari offer
recent ph iii data demonstr voclosporin vc viabl drug lupu nephriti
set stage first approv drug lupu nephriti ln ph iii data
demonstr clear efficaci vs control efficaci data recapitul prior vc efficaci
ln well efficaci benefit demonstr induct w/ calcineurin inhibitor
cni class agent tacrolimu notabl vc chemistri enabl favor pk
profil could provid advantag cni auph dose protocol
could help mitig safeti issu
safeti win w/ ph iii data key though regular dsmb review elimin worst-cas
scenario vc pk profil and/or auph dose protocol came togeth produc
better-than-expect safeti importantli drug pk profil enabl fast-onset
led rapid steroid taper steroid reduct posit attribut doc
pt auph dose protocol guid doc tweak dose base egfr blood
pressur bp top-lin egfr bp data report look clean show stat sig
differ b/w vc tx control arm
ln oppti ripe auph reap benefit first fda-approv
drug ln auph continu build barrier entri cautiou
strength extend ip ln auph note plan lock suppli
chain expect gener manufactur challeng dose protocol ip
deter entrant howev believ possibl manufactur cni could figur
make vc spoke w/ two doc familiar w/ auph dose
protocol doc note monitor egfr bp close adjust dose need
impli protocol label may inform necessari dose
experi w/ vc like inform dose w/ futur gener regardless ip
opportun store auph includ vc vo dri eye syndrom de
fsg -- program expect evolv meaning de ph ii/iii
data expect readout fsg ph iia top-lin data updat
posit expect auph move quickli pursu regulatory/partn path
also ln extens data valuabl commerci w/ futur regulatori
valuat proport futur revenue vc ln po vc de
po vc fsg po base pt assum ln success w/ peak revenue
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
bull pt driven add po data approv ln de fsg bear
pt driven ln patent risk de fsg failur
pleas see import disclosur inform page report
voclosporin vc get approv lupu nephriti
aurora extens studi ln demonstr long-
term yr safety/efficaci vc
vc reason chanc clinic success
vc reason chanc clinic success
ph ii/iii de data expect
pt blend dcf ep multipl
enabl vc solidifi posit ln treatment
pt stay vc long durat add
substanti growth driver market oppti
vc work better-than-expect fsg de trial
readout
ip competit barrier hold auph achiev
peak penetr eu ln
pt blend dcf ep multipl
commerci uptak ln less robust expect
due prefer benlysta high vc price
push doc use tacrolimu base ph iii vc
ip risk pan vc
efficaci fsg superior compar pbo
inferior exist therapi
lead termin program
competitor molecul better safety/efficaci
profil also come competit price
pt blend dcf ep multipl
auph lead asset vc best-in-class calcineurin
inhibitor cni attribut efficaci safeti base
clinic data pt multipl indic
ph iii aurora data show clear superior ln pt
term renal respons compar pbo data
de-risk auph fsg de program
expect adcom eventu approv vc
despit competit assum substanti market share
vc ln fsg de indic given
safety/efficaci profil molecul
 nda submiss ln
 ph ii/iii audrey data de
 ph iia interim data fsg
 project fda adcom vc ln
pleas see import disclosur inform page report
auph initi buy pt
execut summari auph announc posit aurora ph iii trial result demonstr voclosporin vc
superior control lupu nephriti ln importantli data show vc effect safe safeti
overhang program ph iii result elimin overhang facilit regulatori approv path
auph plan file nda potenti launch vc drug fast-act enabl steroid taper
time auph proprietari dose strategi help preserv kidney function could extend ip though cautiou
long-term ip outlook clear need effect approv ln agent posit near-term view
auph w/ much store next two yr
auph lead asset vc design optim novel potenti best-in-class calcineurin inhibitor cni
clinic data patient across multipl indic vc develop treatment lupu nephriti ln
focal segment glomerularsclerosi fsg diseas high unmet need addit topic formul consist voclosporin
ophthalm solut vo evalu treatment dri eye syndrom de
ph iii aurora result show posit efficaci decreas proteinuria safeti egfr bp maintain etc steroid
reduct doc spoke w/ said difficult fda say drug w/ profil global pivot studi
w/ activ ln met primari endpoint renal respons rate vc vs control wk pre-specifi hierarch
secondari endpoint statist signific includ renal respons wk partial renal respons wk time
achiev upcr time reduct upcr robust data also support pre-specifi subgroup analys
age sex race biopsi class region prior mmf use favor vc studi result support differenti vc vs legaci cni -- vc
control activ diseas control rapid diseas progress reduc steroid burden offer conveni aurora extens studi initi w/
patient enrol assess long-term year benefit/risk vc
vc differ rest cni pack expect first fda-approv drug ln estim vc uptak
rapid translat impress launch ramp legaci cni shown toxic
hypertens hyperlipidemia nephrotox data date demonstr vc profil dose strategi mitig
larg extent coupl demonstr efficaci vc provid attract option rheumatologist nephrologist treat ln
current pt treat w/ steroid cellcept cyclophosphamid rituximab cni off-label tacrolimu cyclosporin cni use
transplant set tacrolimu approv ln japan tacrolimu cyclosporin requir close dose adjust patient
monitor less favor profil vc approv option ln make prescrib easi decis doc
vc composit matter ip project last auph method use patent base dose
protocol expect includ drug label extend protect ln howev take
cautiou view long-term ip outlook auph believ dose protocol ip effort lock suppli chain
challeng w/ manufactur vc support entrench provid barrier gener entri howev doc spoke w/
think auph dose protocol essenti seem impress drug differenti efficaci safeti profil
make us somewhat cautiou long-term outlook w/ vc believ gener supplier current manufactur
cni higher chanc figur manufactur vc also dose protocol label may weak
prevent doctor switch gener option b/c anticip doctor gain experi use vc abl
transfer knowledg use gener nonetheless give auph outer-year credit dose protocol expect sticki
delay/prev switch
competitor ln space watch includ near-term benlysta also gazyva would keep eye kzr kzr-
vc mechan action differenti competit drug develop ln sle gsk announc
posit headlin result ph iii trial benlysta belimumab treat ln w/nda also expect submit
sle pt thought half pt ln ln pt avail treatment believ vc
split market w/ benlysta initi gsk auph sale team race get pt tx expect market dynam eventu hit
increment growth peak penetr vc benlysta pt fail benlysta move vc vice versa current care
pt limit doc would prefer agent enabl reduc steroid use better control diseas expect gazyva approv
ln primarili replac rituximab use novel select agent like kzr immunoproteasom inhibitor could help transform ln
tx paradigm still expect cycl one drug next autoimmun diseas progress
auph also develop vc fsg data ln studi posit readthrough fsg help
acceler develop potenti regulatori path conserv estimate peak fsg primari reason
conserv estimate b/c competit risk though ln data de-risk vc potenti
fsg option like rtrx sparsentan reta
bardoxolon could chip away oppti push vc toward later-lin tx option estimate fsg pt similar
preval eu fda ema approv fsg therapi clinic cni use first-lin therapi pt use
intoler steroid auph vc fsg ph ii on-going believ vc success recent ln ph iii readout help de-risk
on-going ph ii fsg also physician alreadi use cni fsg current recept switch less toxic
potenti efficaci next-gen cni like vsc competitor product develop reli differ moa expect
winner take situat fsg
auph pipelin also includ nanomicellar formul vc ophthalm solut vo target dri eye syndrom
de ph ii/iii audrey trial initi top-lin result anticip late estimate peak auph de oppti de market
establish vs ln fsg current approv drug restasi xiidra cequa market de market high
preval estimate affect impli larg market oppti vo test ph ii vs restasi rel higher activ dose vo
vs restasi csa inde led better efficaci notabl safeti compar interestingli ph ii trial design may
flaw sinc primari endpt drop discomfort vs restasi somewhat subject endpt control restasi arm
better expect vo succeed secondari endpt object measur use approv restasi cequa
primari endpt use ph ii/iii ph ii/iii test vs pbo believ favor chanc success believ ph ii
head-to-head secondari endpoint data show vc superior restasi set stage vc compet potenti steal
market share restasi
clinic long-term mainten remiss safeti determin ph iii extens studi signific
improv qualiti life sustain efficaci sle/multi-organ symptom proven
regulatori even vc continu show posit activ on-going trial auph must proceed regulatori
process order eventu market/sel product ex-u market regulatori process
may take longer anticip unforeseen request may delay time market cni drug class histor
run roadblock regulatori approv process eu ex-u path success
anticip fda requir adcom review vc ln prior approv
commerci auph would need effect build salesforc market therapi auph
experi launch product present commerci risk scale manufactur sale forc
optim implement effect market strategi uncertainti remain reimburs payer
term price optim success launch first line treatment ln vs futur competit drug well
prior cheaper off-label drug drug class note japan tacrolimu alreadi approv ln
treatment gsk benlysta alreadi approv sle like get approv ln
financi though current well fund believ auph requir addit capit
rais bring vc market auph open partnership non-u territori futur howev
abl secur partnership may reliant addit potenti dilut capit rais abl bring vc
establish price target auph
base blend two methodolog
use discount cash flow dcf analysi
auph futur cash flow incorpor
discount rate termin growth rate
believ appropri compani
auph size stage develop yield
fair valu
probabl adjust assum overal
likelihood program success would yield share
valuat
also use multipl out-year probability-
weight ep appli multipl
believ appropri given compar
compani ep estim
discount back per year appli
overal likelihood success would yield share
valuat
pv pv termin enterpris net equiti dilut share potenti unadjust share termin growth wacc/discount jefferi estim compani reportstermin growth rate discount rate valuat
establish price target auph
base blend two methodolog
auph valuat multipl probabl
use discount cash flow dcf analysi
auph futur cash flow incorpor
discount rate termin growth rate
believ appropri compani
auph size stage develop yield
fair valu
probabl adjust assum overal
likelihood program success would yield share
valuat
also use multipl out-year probability-
weight ep appli multipl
believ appropri given compar
compani ep estim
discount back per year appli
overal likelihood success would yield share
valuat
discount rate ep multipl futur valuationind probabl successunweight ep contribut ep contribut dri auph expect mileston pipelin
milestonesproducteventtimelinekeyston symposium preclin diabet fda adcom aurora extens fsgsph iia interim opthalm solutionph ii/iii audrey studi nephristi phase iiivoclosporin opthalm solutiondri syndromephas iivoclosporinfoc segment glomerulosclerosisphas iivoclosporin ln voclosporin vc calcineurin inhibitor cni develop lupu nephriti ln
overview vc ln
sle affect peopl women sle patient
develop ln mani ln patient progress esrd
vc immunosuppress inhibit calcineurin lead
blockag express cell-medi immun respons
stabil podocyt kidney
primari endpt show stat sig benefit renal respons rate
voclosporin vs control wk
pre-specifi hierarch secondari endpoint achiev w/ statist
signific favor vc
detail ph iii trial result present like nfk
eular era-edta medic confer
vc potenti address unmet medic need ln
fda ema approv drug ln benlysta gsk approv
adult sle recent april label expand includ pediatr pt yo
activ autoantibody-posit sle receiv soc ph iii ln studi gsk report
posit result co plan file expand label includ ln
posit outlook base aura-lv ph ii aurora ph iii result
vc abl control activ diseas control rapid diseas progress reduc steroid
burden conveni
potenti offer number advantag legaci cni
predict concentr effect tight pk/pd profiledrug monitor need
increas potenc improv impact lipid profil vs cyclosporin csa
auph plan file approv
possibl adcom anticip approv drug launch
sle chronic complex often disabl autoimmun
affect peopl
highli heterogen affect rang organs/tissu
ln inflamm kidney caus sle repres
seriou progress sle
sle patient develop ln
straightforward diseas outcom earli respons assess
measur proteinuria correl w/ long-term outcom
debilit costli often lead esrd dialysi renal
transplant ultim death
mani ln patient progress esrd
sle patient renal damag esrd
fold increas risk prematur death respect
doctor stress achiev remiss quickli ln key reduc organ
damag proport patient progress dialysi
substanti reduc proport patient progress dialysi yr
choic time drug
administr taper
steroid withdraw affect
balanc control
diseas activ damag
organ relat long-term
current treatment paradigm prolif ln use blunt immunosuppress
agent limit safety/efficaci
patient fail achiev cr
week first-lin drug
iv cyclophosphamid monthli
day follow
maximum mg/d taper
cyclophosphamid mg everi week
maximum mg/d month
oral mmf month
mo soc therapi achiev cr
cni suppress immun system common use current prevent
cni reduc cell prolifer inhibit cell differenti also suppress class-switch cell function
make class agent relev tool prevent graft reject autoimmun diseas inflammatori
even though use doc legaci cni limit none
approv ln
auph vc structur analog cyclosporin csa design
optim pk/pd profil intend make drug best-in-class calcineurin
vc cyclic undecapeptid compar
csa vc addit singl
carbon extens double-bond
one side chain
mechanist vc form heterodimer complex
cyclophilin bind inhibit calcineurin
bind calcineurin occur
latch region vc
vc next-gener calcineurin inhibitor
bind inhibit calcineurin calcium-depend serine-
prevent dephosphoryl nfatc transcript
factor block transloc nucleu
express suppress inhibit
growth differenti cell respons
vc cni dual moa potenti improv short- long-
term outcom ln ad cellcept/mmf
inhibit calcineurin vc block express
cni shown abil stabil podocyt kidney
protect podocytopathi proteinuria
stabil actin cytoskeleton within podocyt via
calcineurin inhibit -- potenti diseas modifi ln
structur differ vc lead increas potenc potenti reduc
clinic toxic compar csa
increas potenc vs csa
vc low inter intra patient variabl allow flat dose vs tac csa
modif function group amino lead increas
potenc compar csa low exposur
metabol profil vc chang lead faster elimin
metabolit result lower metabolit exposur compar csa
increas potenc decreas metabolit exposur vc result tighter pk/pd profil vs
csa/legaci cni drug level monitor requir
vc lead less diabet less cholesterolemia compar tac csa
vc show lower incid diabet vs tac
less cholesterolemia csa
cni known induc hyperlipidemia vc profil lead
less cholesterolem csa
vc less advers clinic impact
glucos paramet less
diabetogen tacrolimu renal
vc lower risk induc diabet vs tac
auph report preclin data upcom keyston
symposia conf jan expect show vc
limit neg impact beta cell function provid
insight mechan
favor attribut vc legaci cni prompt auph advanc studi ph ii
auph start ph iib trial aura-lv june complet januari
vc mg bid
week
diagnosi sle accord acr criteria
biopsi proven ln class iv class
alon combin w/class iv
subject achiev complet remiss week
upcr mg/mg
egfr confirm decreas
baselin egfr
presenc sustain low-dos steroid mg
prednison week
administr rescu medic
complet remiss cr week
partial remiss pr week
time cr/pr week sustain
durat cr week
chang baselin selena-sledai week
aura ph ii efficaci vc first agent meet primari secondari
endpoint week global clinic trial activ ln
renal respons remiss week
treatment complet remiss
higher cr week
higher pr reduct upcr baselin week
faster time cr upcr pr
reduct upcr week
-- dose work better higher dose
improv deepen time
aura ph ii composit measur efficaci selena-sledai score
demonstr broader/system benefit vc wk vs control
improv composit
measur show vc
broader benefit patient
autoimmun diseas
also compel data doc
voclosporin bid demonstr statist signific reduct sledai week week
rel control
vc bid demonstr statist signific reduct upcr
dsdna antibodi week major chang egfr bp
upcr also remain stabl
egfr return
baselin week treatment
signific differ blood pressur
week treatment period
dsdna antibodi hallmark auto-immun diseas
although major red flag well-known cni-medi toxic like hypertens hyperlipidemia nephrotox
import watch auph ph iii extens studi
caus ph ii death imbal identifi mitig ph iii
believ issu suffici address hinder approv
cni-rel safeti expect in-lin vc
death report ph ii
common report diarrhea vomit
death occur site limit access soc patient statist differ
baselin demonstr sever form ln potenti comorbid condit poor nutrit
date across multipl indic treat vc in-lin w/ expect class
drug
aurora ph iii studi design mostli ident aura ph ii
taper week
assess efficaci safeti
vc compar placebo
achiev renal respons
week therapi subject
activ lupu nephriti
number subject achiev renal respons week
upcr mg/mg
egfr confirm decreas
baselin egfr
presenc sustain low-dos steroid mg prednison
week
administr rescu medic
diagnosi sle accord acr criteria
kidney biopsi within month studi entri
confirm histolog diagnosi ln
biopsi proven ln class iv class alon
combin w/class iv
partial renal respons week
time reduct upcr baselin week
renal respons week
durat renal respons week
chang baselin lab paramet week
renal respons low-dos steroid week
chang baselin selena-sledai week
aurora ph iii press releas substanti efficaci benefit
safeti profil vc standard care control group
overal vc well toler w/ unexpect sae
sae vc patient vs control arm
infect vc patient vs control
vc treatment result signific decreas
egfr increas blood pressur lipid glucos
importantli vc caus death
death control group
robust data also support pre-
region prior mmf use favor vc
achiev statist signific renal respons rate vc vs control wk
achiev pre-specifi hierarch secondari endpoint statist signific favor vc
renal respons week partial renal respons week time achiev upcr time
reduct upcr
odd ci voclosporin endpointsvoclosporin controlhazard ratiovoclosporin controlhazard ratioparti renal respons upcr reduct upcrp respons renal respons endpointren respons aurora ph iii extens studi bolster overal safeti
follow week treatment
aurora studi ln patient
continu receiv background therapi
mmf and/or oral prednison start
dose end
enrol
assess long-term safeti toler vc compar
placebo addit month
complet treatment aurora studi ln subject
subject complet week
treatment studi drug aurora studi
subject will continu take oral mmf
durat studi
advers event ae profil routin biochem hematolog
assess month
proport subject renal respons month
proport subject partial renal respons reduct
baselin upcr month
renal flare adjud clinic endpoint committe
chang aurora baselin selena-sledai month
chang upcr aurora baselin month
chang egfr aurora baselin month
chang urin protein serum creatinin aurora baselin
month
chang immunolog paramet anti-dsdna aurora
baselin month
studi requir approv data valuabl commerci w/ futur reg interact
vc composit protect potenti method
protect howev cautiou method ip
auph anticip upon regulatori approv patent
protect vc extend eu
japan least octob hatch-
waxman act compar law countri
april anticip pediatr
 patent also issu cover vc dose protocol method use term
extend
competit landscap look extens ln sle success rate low w/
posit ph iii data believ vc posit favor
vc differenti mechan action compar competit drug ln sle
space believ vc posit favor get approv
benlysta like get label expans
includ ln approxim time
mmf azathioprin fda-
approv ln base
prescrib off-label ln
doc spoke w/ said drug fda-approv label ln influenc prescrib
market model lupu nephriti
lupu lntotal preval total w/ definit total moderate-sever patient total w/ lupu nephriti ln elig treatment net annual sale compani report jefferi llc lntotal eu preval total w/ definit total moderate-sever patient total w/ lupu nephriti ln elig treatment net eu sale assum eu revenu auph total eu revenu voclosporin vc calcineurin inhibitor cni target
overview vc fsg
incid patient fsg year nephrot syndrom
symptom indic kidney damag patient fsg upon biopsi
vc immunosuppress synergist dual mechan
action inhibit calcineurin vc block express t-cell mediat
immun respons may stabil podocyt kidney
proof concept ph iia on-going
studi design evalu safeti efficaci vc first-lin therapi fsg
ph iia start interim result expect
fsg rare diseas attack kidney filter unit glomeruli
caus seriou scar sclerosi lead perman kidney
damag even failur
incid patient fsg year
nephrot syndrom symptom indic kidney
damag patient fsg upon biopsi
fda ema approv fsg therapi
injuri loss podocyt small cell glomeruli key
featur fsg inflamm lead diseas progress
hyperlipidemia hypoalbuminemia
patient suscept infect embol
leakag blood protein urin proteinuria
clinic sign fsg
lack control proteinuria result esrd impli dialysi
efficaci prolong steroid therapi
idiopath adult fsg
initi treatment fsg
immunosuppress therapi patient
alternate-day week complet
remiss achiev
corticosteroid taper slowli month
calcineurin inhibitor first-lin therapi
patient rel contraind
intoler steroid
fsg proof concept ph iia studi design
cohort subject vc dose determin analysi efficaci safeti data week
first subject cohort
treatment-nav receiv limit steroid treatment
proteinuria upcr mg/mg
proport subject achiev complet partial remiss week
cr defin urinari protein/creatinin ratio upcr mg/mg
pr defin upcr mg/mg mg/mg reduct upcr baselin
competit landscap fsg
moa unclear bind podocyt receptor
hyperact immun cell activ diseas
angiotensin receptor blockad endothelin
pathway activ nfb
fuse extracellular
believ high unmet need diseas set lower bar clinic success room
sever option develop work fsg
treatment paradigm fsg still tbd base vc profil anticip would
use later option exist
market model fsg
focal segment fsgstotal popul number individu elig wac revenu compani report jefferi llc fsgstotal eu popul number individu elig net eu revenu eu sale voclosporin opthalm solut vo target dri syndrom de
overview vo de
incid estim patient diagnos de
establish reg pathway de defin approv process cni
vc immunosuppress inhibit calcineurin vc block
express t-cell mediat immun respons vo ophthalm
solut nano-micellar vc
ph ii result demonstr vo vc administ twice
daili superior restasi cyclosporin administ twice daili
across object endpoint includ fc
strong ip portfolio vo
de chronic inflammatori eye diseas character
irrit inflamm occur eye tear
film compromis reduc tear product imbalanc
tear composit excess tear evapor
estimate patient diagnos de
control symptom consid inadequ
diseas incid may grow
independ
patient demand better control symptom persist
va scale discomfort
worst discomfort
chang baselin individu
sensat photophobia eye pain eye dryness
itch va score day
chang baselin symptom assess dri
score sand day
chang baselin unanesthet schirmer test
score day
chang baselin fluorescein corneal stain
fc total score day
restasi bid
eye day
evalu toler efficaci
safeti vo versu restasi
subject mild moder
best correct visual acuiti bcva eye
logmar
document on-going dri eye diseas
symptom sever score dryness va
scale score mm mm per
minut total fluorescein stain score least
ph ii result report vo meet primari endpoint
superior restasi key secondari endpoint de patient
drop discomfort score low vo restasi
differ stat sig/clin meaning
vo statist superior restasi achiev
increas week
primari endpoint met
differ success w/
vo secondari endpoint
use ph iii
primari endpt
analysi requir
fda restasi approv
vo higher concentr api per drop restasi vs clear solut vs microemuls
vo achiev high concentr target eye tissu shown rabbit model preclin data
vo potenti dose daili rapid onset action shown rabbit studi
limit w/ ph ii vo restasi well toler drop discomfort score
primari endpoint low group suggest trial design/primari endpoint sub-optimal
ph ii vo show potenti best class therapi improv
tear volum de patient
improv tear volum de patient
fc vo vs restasi week
fluorescein corneal stain fc
note treatment
statist signific improv
sand score baselin week
note approv indic restasi
cequa de
vo show statist signific improv dri sign vs restasi symptom vs baselin
seriou advers event sae report
advers event mild moder major larg expect
treatment show improv baselin week
meaning chang baselin either treatment group
meaning chang baselin either treatment group
toler toler low drop discomfort score upon applic
design audrey ph ii/iii dose-rang studi vo vs vehicl
compar
vehicl
administ
eye bid week
assess safeti efficaci vo
compar
vehicl subject w/ de
proport subject mm increas
baselin schirmer tear test week
primari end point base upon establish approv pathway
topic applic cyclosporin de patient
conc restati
use ph ii
dri eye eye support clinic diagnosi
symptom sever score dryness va
scale anesthet score mm
mm per minut total fluorescein stain score
chang baselin dryness va subject
baselin dryness va score
scale discomfort maxim
discomfort week
current treatment regimen de
basi fda approv
increas schirmer wet score
mm moth
increas schirmer wet score
mm week
score improv eye dryness
score week
calcineurin inhibit valid mechan treatment ocular surfac diseas howev
opportun potenti improv effect enhanc toler onset action
allevi need repetit dose
competit landscap dri syndrom de
mucu penetr particl deliveri
vo succe ph ii/iii get approv believ total data ph ii head-to-head vs restasi ph ii/iii multi-
dose data make compel case vo approv potenti vo prefer option de
restasi current largest share de market w/ revenu set
stage vo potenti disrupt displac
market model dri
dri dri total dri diseas de moderate-sever diseas pt w/ acut flare -- elig wac sale compani report jefferi llc dri total eu dri diseas de moderate-sever diseas pt w/ acut flare -- elig net eu sale eu sale royalti assum revenu manag financi
mr greenleaf signific execut manag
leadership corpor develop
commerci oper experi biopharmaceut industri join auph april
ceo prior serv ceo ceo chairman sucampo pharmaceut
acquir ceo member board director histogen corpor
work medlmmun global biolog arm astrazeneca svp commerci oper
recent presid
dr solomon co-found privately-held experienc
pharmaceut physician year clinic develop medic affair experi
larg pharma biotech recogn expert rare-diseas drug develop neil join
aurinia vifor pharma formerli held posit vice-president
lead clinician develop cellcept rare diseas neil led cellcept clinic
develop team peopl saw complet report public studi
pemphigu vulgari myasthenia gravi industri first success landmark lupu
nephriti studi call alm prior neil work roch global clinic develop
medic affair transplant virolog auto-immun diseas roch led divers
team develop implement post-market studi budget exceed
million transplant cellcept zenapax virolog cytoven franchis
mr bourgeault cfo compani sinc tenur contribut
significantli one largest canadian biotechnolog pipe transact total million us
dollar involv multi-million dollar roch licens agreement voclosporin
addit play crucial role execut merger isotechnika privat
held septemb
auph incom thousand except per share revenues- dri revenues- fsg revenues- licens contract total good gross oper expens research gener total oper income/loss incom expens interest incom expens incom total incom pre-tax provis incom net net ep attribut common averag share use comput net dilut share balanc sheet
auph balanc sheet thousand except price fy asset cash term receiv accru int expens current trial contract ip stockhold equitycurr liabilitiesaccount payabl accru portion defer current warrant equitycommon stock comprehens sharehold deficit liabil sharehold statement flow
auph statement flow thousand except price fy activ net reconcil net loss net cash use oper activ depreci consider mileston oper asset liabil net chang oper cash use oper activ proce purchas purchas properti patent cash use invest activ net proce issuanc common exercis warrant stock cash provid financ exchang rate cash cash equival restrict cashnet decreas increas cash cash equival restrict cash equival begin equiti research
aurinia clinic stage biopharma compani focus develop commerci therapi treatment lupu nephriti
pt blend dcf probability-adjust ep risk efficaci toxic commerci regulatori competit
